Physician profile
Anika Michael
NPI 1619174646
$2,497.89
in general payments reported to CMS, 2019-2025
10 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $146 · 2022: $792 · 2023: $219 · 2024: $569 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $845.35 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $756.14 | 2022-2025 | |
| Alcon Vision LLC | $176.13 | 2024-2025 | Hydrus Microstent, Simbrinza |
| Ivantis, INC | $146.19 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $130.88 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $125.00 | 2025 | Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $124.94 | 2019 | |
| Rxsight INC | $97.91 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Amgen INC. | $58.32 | 2025 | Tepezza |
| Glaukos Corporation | $37.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anika Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.